Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Breast 2Head & Neck 1CNS 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Epilepsy 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × LY3295668 erbumine × Breast × Clear all
NCT03092934 2021-07-02

A Study of AK-01 (LY3295668) in Solid Tumors

Eli Lilly and Company

Phase 1/2 Completed
13 enrolled 17 charts
BreastHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03955939 2020-06-01

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Eli Lilly and Company

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡